1. Home
  2. NATL vs MLYS Comparison

NATL vs MLYS Comparison

Compare NATL & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo NCR Atleos Corporation

NATL

NCR Atleos Corporation

HOLD

Current Price

$47.99

Market Cap

3.0B

Sector

N/A

ML Signal

HOLD

Logo Mineralys Therapeutics Inc.

MLYS

Mineralys Therapeutics Inc.

HOLD

Current Price

$28.60

Market Cap

2.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NATL
MLYS
Founded
2023
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.0B
2.4B
IPO Year
2023
2023

Fundamental Metrics

Financial Performance
Metric
NATL
MLYS
Price
$47.99
$28.60
Analyst Decision
Hold
Strong Buy
Analyst Count
5
7
Target Price
$42.28
$47.33
AVG Volume (30 Days)
870.1K
994.8K
Earning Date
06-01-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
73.98
N/A
EPS
2.14
N/A
Revenue
$4,354,000,000.00
N/A
Revenue This Year
$5.99
N/A
Revenue Next Year
$4.53
N/A
P/E Ratio
$22.58
N/A
Revenue Growth
0.86
N/A
52 Week Low
$22.30
$9.69
52 Week High
$48.40
$47.65

Technical Indicators

Market Signals
Indicator
NATL
MLYS
Relative Strength Index (RSI) 76.92 41.76
Support Level $35.19 $26.85
Resistance Level N/A $30.05
Average True Range (ATR) 1.93 1.46
MACD 0.67 0.24
Stochastic Oscillator 97.03 40.98

Price Performance

Historical Comparison
NATL
MLYS

About NATL NCR Atleos Corporation

NCR Atleos Corp is financial technology company providing self-directed banking solutions to a customer base including financial institutions, merchants, manufacturers, retailers and consumers. Self-directed banking is a rapidly growing, secular trend that allows banking customers to transact seamlessly between various channels all for the same transaction. Their comprehensive solutions enable the acceleration of self-directed banking through ATM and interactive teller machine (ITM) technology, including software, services, hardware and its proprietary Allpoint network. Atleos manage its operations in the following segments which includes Self-Service Banking, Network, and Telecommunications abd Technology.

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.

Share on Social Networks: